I-Mab Stock: Market Experts Foresee Significant Upside

Despite facing recent downward pressure on its share price, I-Mab continues to receive a largely favorable assessment from market analysts. The sentiment shift was highlighted when Wall Street Zen upgraded the biotech firm to a “Buy” recommendation, signaling growing confidence in the company’s strategic direction and future outlook.

Strong Quarterly Performance Defies Trend

The current price trend appears disconnected from the company’s latest financial performance. For the second quarter of 2025, I-Mab reported an earnings per share (EPS) of ($0.07), which surpassed analyst projections of ($0.10) by $0.03. This positive earnings surprise typically indicates stronger underlying operational execution than the market had anticipated.

This improved financial trajectory is further supported by HC Wainwright’s revised forecast for the third quarter of 2025. The research firm raised its EPS estimate from ($0.09) to ($0.05), pointing toward a brighter near-term financial picture.

Price Targets Signal Substantial Gains

This optimistic view is echoed by other leading research institutions. Needham & Company LLC increased its price target for I-Mab shares from $5.00 to $6.00, while maintaining its “Buy” rating. In a similar move, HC Wainwright reaffirmed its “Buy” rating and established a $7.00 price target. The current consensus price target stands at $6.50, implying considerable upside potential from recent trading levels.

Should investors sell immediately? Or is it worth buying I-Mab?

Institutional Confidence and Pipeline Progress

The belief in I-Mab’s long-term value is reflected in substantial institutional ownership, with approximately 38.38% of its equity held by these major investors. Notably, Millennium Management LLC aggressively expanded its stake by 763.1% during the fourth quarter, acquiring a new position of 97,749 shares.

This institutional commitment is bolstered by concrete progress in the company’s clinical development pipeline. I-Mab recently completed patient recruitment for a Phase 1b dose expansion study of Givastomig, a key bispecific antibody being developed as a first-line treatment for gastric cancer. Earlier Phase 1b data demonstrated an impressive 83% response rate when the therapy was combined with immunochemotherapy.

In a strategic move to strengthen its intellectual property position, I-Mab acquired Bridge Health Biotech. This acquisition secured crucial upstream rights to the CLDN18.2 antibody related to Givastomig.

Technical Perspective

From a technical analysis standpoint, I-Mab’s stock currently trades with a 50-day moving average of $2.91 and a 200-day moving average of $1.71. Over the past twelve months, the shares have traded within a wide range of $0.60 to $5.90, reflecting the inherent volatility of the biopharmaceutical sector. The present price decline remains within this established range and continues to be monitored closely by market participants.